Shots:
- Chiesi Group has entered into an exclusive global collaboration & license deal with Arbor for ABO-101 in primary hyperoxaluria type 1 (PH1) & a multitarget option to use Arbor’s gene editing platform for developing liver-targeted therapies for rare diseases
- As per the deal, Chiesi will obtain exclusive rights to develop & commercialize ABO-101 for PH1 & use Arbor’s knockout & reverse transcriptase editing tech for rare diseases in exchange for ~$115M in upfront & near-term payments, ~$2B in milestones, & up to low double-digit tiered royalties
- Additionally, Arbor & Chiesi will collaborate on the ongoing P-I/II (redePHine) trial assessing safety, tolerability, PK/PD, & preliminary efficacy of single dose ABO-101 for PH1
Ref: Chiesi Group | Image: Chiesi Group and Arbor Biotechnologies | Press Release
Related News:- Hinge Bio Collaborates with Kyorin Pharmaceutical to Advance HB2198 in Japan for Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
